Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition

Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease

(2015) M Llopis et al.   GUT

Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse Model

(2015) Jane M. Natividad et al.   INFLAMMATORY BOWEL DISEASES

Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases

(2015) Herbert L. DuPont   MAYO CLINIC PROCEEDINGS

Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?

(2015) Debbie L Shawcross   Expert Review of Gastroenterology & Hepatology

Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver

(2014) Hendrik Vilstrup et al.   HEPATOLOGY

A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS

(2014) Genta Kakiyama et al.   JOURNAL OF LIPID RESEARCH

Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats

(2013) Dabo Xu et al.   GASTROENTEROLOGY

Altered profile of human gut microbiome is associated with cirrhosis and its complications

(2013) Jasmohan S. Bajaj et al.   JOURNAL OF HEPATOLOGY

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

(2013) Jasmohan S. Bajaj et al.   PLoS One

A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids

(2012) Lotta K. Stenman et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Linkage of gut microbiome with cognition in hepatic encephalopathy

(2011) Jasmohan S. Bajaj et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells

(2011) Andrea Mencarelli et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Bile Acid Is a Host Factor That Regulates the Composition of the Cecal Microbiota in Rats

(2011) K.B.M. Saiful Islam et al.   GASTROENTEROLOGY

Extending Biochemical Databases by Metabolomic Surveys

(2011) Oliver Fiehn et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice

(2011) Qiang Zhu et al.   JOURNAL OF HEPATOLOGY

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

(2011) Mark Pimentel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metagenomic biomarker discovery and explanation

(2011) Nicola Segata et al.   GENOME BIOLOGY

Quantitative Assessment of the Human Gut Microbiome Using Multitag Pyrosequencing

(2010) Patrick Gillevet et al.   CHEMISTRY & BIODIVERSITY

Drug therapy: Rifaximin1

(2010) Jasmohan S. Bajaj et al.   HEPATOLOGY

Rifaximin Treatment in Hepatic Encephalopathy

(2010) Nathan M. Bass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Experimental models of hepatic encephalopathy: ISHEN guidelines

(2009) Roger F. Butterworth et al.   LIVER INTERNATIONAL

Gut ammonia production and its modulation

(2008) Manuel Romero-Gómez et al.   METABOLIC BRAIN DISEASE